Clinical trials: Exophthalmos, open to volunteers
Thyroid Eye Disease (TED), Graves' Disease
Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
The primary objective of study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ETHY-001 in healthy volunteers and participants with Thyroid Eye Disease after single subcutaneous doses.
- Conditions
- Thyroid Eye Disease (TED), Graves' Disease, Eye Diseases, Hereditary, Eye Diseases
- Trial name
- NCT07885605
- Testing
- ETHY-001
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ethyreal Bio, Inc.
Artifical Intelligence, Cataract
Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the Eye
This is a multi-center, cross-sectional study evaluating a smartphone-based artificial intelligence (AI) system for anterior segment eye disease screening.
- Conditions
- Artifical Intelligence, Cataract, Pterygium, Keratopathy
- Trial name
- LENS (NCT07634913)
- Testing
- Smartphone-based on-device artificial intelligence system for anterior segment eye disease screening
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Thyroid-Associated Ophthalmopathy
Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease
The purpose of this study is to determine whether Sirolimus is more effective and burdened with less side effects than conventional treatment with corticosteroids in patients with active thyroid eye disease.
- Trial name
- NCT04936854
- Testing
- Sirolimus 1 mg Oral Tablet, Methylprednisolone
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- Haukeland University Hospital
Thyroid Eye Disease, Graves Orbitopathy
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24.
- Conditions
- Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases
- Trial name
- NCT06112340
- Testing
- linsitinib
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- Sling Therapeutics, Inc.